What question did this study set out to answer?

To evaluate the pharmacological rationale, antitumor efficacy, and organ toxicity of continuous intravenous infusion compared to bolus injection in cancer chemotherapy.

December 1, 1983Annals of Internal Medicine

Continuous Infusion or Bolus Injection in Cancer Chemotherapy

View Full Paper

Ask AI

Bookmark

Why the study?

Does continuous intravenous infusion of anticancer drugs improve antitumor effects and reduce toxicity compared to bolus injection in cancer patients?

Population

Cancer patients receiving chemotherapy

Comparison

Continuous intravenous infusion of anticancer… vs Bolus injection

Design

Review

Authors

RCRobert W. CarlsonNational Comprehensive Cancer Network

Discussion

Member takes

Implication

Continuous infusion of chemotherapy agents may reduce specific toxicities, including doxorubicin-induced cardiotoxicity, but requires validation in randomized controlled trials.

Key Points

To evaluate the pharmacological rationale, antitumor efficacy, and organ toxicity of continuous intravenous infusion compared to bolus injection in cancer chemotherapy.
Synthesized pharmacological evidence regarding cell cycle-specific cytotoxic mechanisms and drug half-lives for continuous versus bolus drug delivery.
Evaluated preclinical and clinical reports assessing tissue-specific toxicities and the feasibility of ambulatory infusion pump technology.
Continuous drug exposure to cell cycle-specific agents, including cytarabine and bleomycin, substantially enhanced antitumor activity in cell cultures and animal models.
Continuous infusion regimens qualitatively mitigated severe toxicities in normal tissues, notably bleomycin pulmonary toxicity, doxorubicin cardiotoxicity, and fluorouracil myelosuppression.
Most existing clinical studies comparing delivery schedules are uncontrolled, indicating a lack of definitive evidence to establish standardized continuous infusion protocols.

Structured PICO

Does continuous intravenous infusion of anticancer drugs improve antitumor effects and reduce toxicity compared to bolus injection in cancer patients?

Population

Cancer patients receiving chemotherapy

Intervention

Continuous intravenous infusion of anticancer drugs (e.g., cytarabine, bleomycin, doxorubicin, fluorouracil)

Comparator

Bolus injection

Outcome

Antitumor effects and toxicity (including pulmonary, cardiac, and myelosuppression)

Continuous infusion of chemotherapy agents may reduce specific toxicities, including doxorubicin-induced cardiotoxicity, but requires validation in randomized controlled trials.

Limitations

most clinical studies of the continuous infusion of anticancer drugs have been uncontrolled

Cite This Study

Robert W. Carlson (1983) studied this question.

synapsesocial.com/papers/6a7cf4877396d1123d91b2f7 https://doi.org/10.7326/0003-4819-99-6-823

View Full Paper

Ask AI

Bookmark

Implication

Continuous infusion of chemotherapy agents may reduce specific toxicities, including doxorubicin-induced cardiotoxicity, but requires validation in randomized controlled trials.

Continuous Infusion or Bolus Injection in Cancer Chemotherapy

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Continuous Infusion or Bolus Injection in Cancer Chemotherapy

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Also Consider

Also Consider